DUC TRIEU: Open Payments
NPI 1659317576 · SOUTH BOSTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$331 in 18 payments from 8 companies in 2025. Trend: 2023 $178 · 2024 $340 · 2025 $331
Food & beverage: $331
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $141 |
| Indivior Inc. | 2 | $44 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Dexcom, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Novo Nordisk Inc | 1 | $15 |
Products named: Kerendia, SUBLOCADE, BREZTRI, XIFAXAN, Dexcom G6 Transmitter, CAPLYTA, MOUNJARO, Wegovy.
Industry payments across VA — which companies pay providers there.
